Repro Med Systems (NASDAQ: KRMD) is one of 133 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Repro Med Systems to similar companies based on the strength of its dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Repro Med Systems and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repro Med Systems 0 0 1 0 3.00
Repro Med Systems Competitors 1229 3966 6549 381 2.50

Repro Med Systems presently has a consensus price target of $12.00, indicating a potential upside of 35.44%. As a group, “Surgical & medical instruments” companies have a potential upside of 9.83%. Given Repro Med Systems’ stronger consensus rating and higher probable upside, research analysts clearly believe Repro Med Systems is more favorable than its competitors.

Volatility and Risk

Repro Med Systems has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Repro Med Systems’ competitors have a beta of 1.02, suggesting that their average stock price is 2% more volatile than the S&P 500.

Insider and Institutional Ownership

61.3% of Repro Med Systems shares are held by institutional investors. Comparatively, 47.7% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 39.0% of Repro Med Systems shares are held by insiders. Comparatively, 14.6% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Repro Med Systems and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repro Med Systems 4.48% 10.02% 7.86%
Repro Med Systems Competitors -718.79% -73.80% -21.43%

Valuation and Earnings

This table compares Repro Med Systems and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Repro Med Systems $23.16 million $560,000.00 886.00
Repro Med Systems Competitors $1.42 billion $147.39 million -31.67

Repro Med Systems’ competitors have higher revenue and earnings than Repro Med Systems. Repro Med Systems is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Repro Med Systems beats its competitors on 9 of the 13 factors compared.

About Repro Med Systems

Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.

Receive News & Ratings for Repro Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.